DANAHER CORP /DE/
No SEC Form 4 filings for $DHR in the last 30 days.
See all $DHR insider activity →Barclays maintained an 'Overweight' rating on Danaher (DHR) and raised its price target to $255 from $230. The company's GF Value™ suggests it is 8.1% undervalued, while its GF Score™ is 82/100. Insider activity shows significant selling, with $12.7M in sales over the last three months. Danaher operates in healthcare, with a market cap of $151.94B.
Danaher (DHR) plans to launch an AI-powered autonomous lab by early 2027 to accelerate drug discovery, aiming for 8x faster progress and 10x more reagents annually. The lab integrates AI, robotics, and capabilities from multiple Danaher companies, with collaboration from Automata.
Danaher (DHR) shares rose 2% premarket after announcing plans for an AI-powered autonomous lab for antibody research, expected to launch in early 2027. The lab aims to speed up discovery and increase reagent generation. Barclays raised DHR's price target to $255 from $230, maintaining an Overweight rating.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning DHR (DANAHER CORP /DE/). Coverage has skewed bullish: 6 bullish, 3 neutral, and 0 bearish.
Recent DHR coverage spans financial news, technology and earnings.
The analyst price-target raise is a near-term sentiment tailwind, but it is not a new fundamental datapoint beyond the brokerage view.
Long‑term positive outlook as the lab could accelerate reagent development, but no immediate financial impact.
The announcement introduces a new growth avenue and may boost investor sentiment.
Analyst upgrade with higher price target may attract buying interest.
Analyst rating upgrade may attract buying interest.
AlphAI scores every news story that mentions DHR with an AI model for sentiment and relevance, and aggregates insider trades from DANAHER CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Barclays maintained an 'Overweight' rating on Danaher (DHR) and raised its price target to $255 from $230. The company's GF Value™ suggests it is 8.1% undervalued, while its GF Score™ is 82/100. Insider activity shows significant selling, with $12.7M in sales over the last three months. Danaher operates in healthcare, with a market cap of $151.94B.
4 min readDanaher (DHR) plans to launch an AI-powered autonomous lab by early 2027 to accelerate drug discovery, aiming for 8x faster progress and 10x more reagents annually. The lab integrates AI, robotics, and capabilities from multiple Danaher companies, with collaboration from Automata.
1 min readDanaher (DHR) shares rose 2% premarket after announcing plans for an AI-powered autonomous lab for antibody research, expected to launch in early 2027. The lab aims to speed up discovery and increase reagent generation. Barclays raised DHR's price target to $255 from $230, maintaining an Overweight rating.
2 min readRBC Capital maintained an 'Outperform' rating for Danaher Corp (DHR) and raised its price target to $250.00 from $215.00. The stock is currently trading at $214.21, with a GF Value™ of $235.16, indicating it is 8.9% undervalued. Danaher has a GF Score™ of 82/100, reflecting strong performance. Insider activity shows significant selling, with $12.74 million in sales over the last three months.
1 min readRBC Capital maintained an Outperform rating on Danaher with a $250 price target, implying a 16.8% upside from the Oct 2 close. The firm cited a positive outlook for bioprocessing demand and market confidence as key factors.
1 min readGE HealthCare appointed Rodolphe Katra as Global Chief AI Officer, expanding AI use in medical devices. Danaher announced Shashanka Muppaneni as Chief Strategy Officer. Enhertu, developed by AstraZeneca and Daiichi Sankyo, received EU and UK recommendations for breast cancer treatment. Fresenius Medical Care and NHS are building the UK's first net-zero dialysis center.
2 min readDanaher (DHR) shares fell 3.9% after Julie Sawyer Montgomery became CEO, replacing Rainer Blair. The company projected 3-4% core revenue growth for 2026, citing deferred biopharma equipment shipments. Shares closed at $211.71, down 4.5%. Danaher's Q3 results are due October 21. The stock is down 7.7% YTD and 12.1% from its 52-week high.
2 min readDanaher Corporation (DHR) announced Julie Sawyer Montgomery as its new President and CEO. The leadership transition may signal strategic changes, according to AI Analyst.
1 min readDanaher's DHR Biotechnology segment reported 4% YoY sales growth to $1.92B in Q2 2026, driven by China demand and bioprocessing business. Despite regional challenges, DHR expects mid-single-digit core revenue growth for 2026. CVS Health and Labcorp peers also reported segment growth. DHR shares gained 5.9% in a month, trading at 24.92X forward P/E.
1 min readGilead Sciences (GILD) reports 10% growth in non-Veklury sales, 12% rise in HIV sales, and raises 2026 outlook. Danaher (DHR) shows signs of recovery with 5.5% revenue growth and strong bioprocessing orders but faces respiratory testing weakness and reduced growth outlook.
3 min read
